Abstract:Abstract Cell-cycle arrest, apoptosis, and senescence are widely accepted as the major mechanisms by which p53 suppresses tumor formation. Nevertheless, it remains unclear how these p53 responses are differentially controlled in vivo and whether they are absolutely required for tumor suppression. p53 is regulated by an exquisite network of fine-tuning mechanisms that ensure proper responses to the various stress signals encountered by cells. In broad terms, p53 activities are controlled via protein levels, coactivator/corepressor recruitment, and a diverse array of post-translational modifications that includes acetylation, ubiquitination, phosphorylation, methylation, sumoylation, and neddylation. p53 was the first non-histone protein shown to be regulated functionally by acetylation and deacetylation and subsequent work has established that acetylation plays a major role in controlling promoter-specific activation of p53 targets during stress responses. We and others recently showed that p53 is acetylated at K120 by Tip60/MOF, while K164 is acetylated by CBP and p300, but not Tip60/MOF. Both sites are mutated in human tumors and well conserved in all species known to encode p53. Interestingly, K120 acetylation is crucial for p53-mediated apoptosis but has no obvious effect on cell cycle arrest, while simultaneous loss of acetylation at all major sites abolishes the ability of p53 to induce both cell cycle arrest and apoptosis, suggesting that acetylation is essential for both p53-mediated processes. Nevertheless, the role of acetylation in the most critical aspect of p53 function, its capacity to suppress tumor formation, has not been addressed. To investigate whether p53 acetylation is important for tumor suppression, we generated p53-mutant mice (p53K117R/K117R) in which K117 (K120 in human) is replaced by arginine. In these animals, p53-mediated apoptosis is abrogated but p53-dependent cell cycle arrest and senescence remain intact. We also established mice (p533KR/3KR) in which the three acetylation sites of the DNA-binding domain (K117, K161, K162) were simultaneously replaced by arginine. Significantly, loss of acetylation at these three sites completely abolished the ability of p53 to mediate cell cycle arrest, apoptosis, and senescence in vivo. To evaluate whether these p53-dependent processes are required for tumor suppression, we monitored tumor formation in cohorts of p53 acetylation-deficient mice. Although p53-null mice rapidly develop spontaneous thymic lymphomas, neither p53K117R/K117R nor p533KR/3KR mice are prone to early-onset tumorigenesis. Since tumor suppression can be mediated by a p53 polypeptide (e.g., p533KR) that lacks the ability to induce p53-dependent cell cycle arrest, apoptosis, and senescence, these results indicate that other aspects of p53 function are sufficient to suppress tumor formation. Notably, p533KR retains the ability to modulate energy metabolism and reactive oxygen species (ROS) production by regulating metabolic target expression. These findings underscore the crucial role of acetylation in differentially modulating p53 responses and suggest that unconventional activities of p53, such as metabolic regulation and antioxidant function, are critical for suppression of early-onset spontaneous tumorigenesis. Our study thus reveals that current views regarding the mechanism of p53-mediated tumor suppression should be reconsidered. Citation Format: Tongyuan Li, Ning Kon, Le Jiang, Ying Zhao, Richard Baer, Wei Gu. Tumor suppression in the absence of p53-mediated cell cycle arrest, apoptosis, and senescence. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr SY02-02. doi:10.1158/1538-7445.AM2013-SY02-02

Abstract 5644: The impact of ATF3, JDP2, FOXR2, NAA10, FOXL2, DDX20, and p14ARF on the transactivation of p53

Abstract 830: ZFP14, a p53 target, suppresses tumor formation by regulating HOXA gene cluster expression

Abstract 1037: Targeting the RBM38-EIF4E Complex to Increase Wild-Type P53 As a Novel Cancer Therapeutic Strategy

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Negative Regulation of p53 Functions by Daxx and the Involvement of MDM2

Abstract 4491: Modulation of P63 Expression by Phosphorylation of RBM38 at S195 Via Mir-203

Abstract P10: p44, the Amino-terminal Lacking Isoform of p53, is Dispensable for Tumor Suppression but Regulates Male Fertility

Abstract SY02-02: Tumor Suppression in the Absence of P53-Mediated Cell Cycle Arrest, Apoptosis, and Senescence.

Abstract 2585: Mutant P53 Gains Oncogenic Functions Through a Cytosolic DNA Response

Abstract A042: Differences in Gain-of-function and Inhibitory Effects Amongst P53 Mutants in Vivo

The Activating Transcription Factor 3 Protein Suppresses the Oncogenic Function of Mutant p53 Proteins

Abstract 1284: Estrogen Receptor Alpha Transcriptionally Regulates P53 in MCF7 Human Breast Cancer Cells

Abstract 2633: TP53 Loss Creates Therapeutic Vulnerability in Cancer

Abstract 5646: Altered intronic polyadenylation by mutant p53 impairs transcription of DNA repair genes in lung cancer

Abstract B087: Mutant-p53 amplifies Cxcl1 expression from distal enhancers blunting immune checkpoint inhibition efficacy in pancreatic cancer

Deciphering the acetylation code of p53 in transcription regulation and tumor suppression

Abstract B006: P53 transcriptional regulation of transposable elements and the downstream immune response in ovarian cancer

Differences in gainof-function and inhibitory effects amongst p53 mutants in vivo

Abstract A15: Elucidating the Role of P53 in the Cellular Origins of Pancreatic Cancer Development

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

Multiple roles of p53 in cancer development: Regulation of tumor microenvironment, m6A modification and diverse cell death mechanisms